Centrum Diagnostyczno Lecznicze Barska Sp. z o.o. — Clinical Trial Site

12 Registered trials

3 Currently recruiting

Organisation

Centrum Diagnostyczno Lecznicze Barska Sp. z o.o.

Location

Wloclawek, Poland

Identifier

ORG-100046484

Address

Ul. Barska 13, 87-800, Poland

Departments

Gastroenterology
Gastroenterology Department
N/A
NA
Oddział Gastroenterologii
Oddział Szpitalny
PL10017: Poradnia Gastroenterologiczna
PL10020: Poradnia Gastroenterologiczna
PL10033:Gastroenterology
PL10039_Gastroenterology
Szpital Specjalistyczny Barska

Clinical trials at this site (12)

Search interface

A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a… Recruiting

2023-509606-30-00 Ulcerative colitis 5 2024-07-24
Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting

2025-521382-27-00 Moderately to Severely Active Crohn's Disease 10 2025-12-04
A clinical study of tulisokibart in people with Crohn’s disease or ulcerative colitis (MK-7240-011) Recruiting

2024-513533-20-00 Crohn’s Disease or Ulcerative Colitis 5 2025-02-25
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended

2023-508636-61-00 Crohn’s Disease 5 2024-10-24
Dose-finding study of SAR443122 in adult participants with ulcerative colitis Ended

2022-500290-14-01 Colitis ulcerative 4 2023-05-11
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504741-32-00 Moderately to Severely Active Crohn's Disease 4 2022-11-30
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended

2023-504743-13-00 Moderately to Severely Active Ulcerative Colitis 4 2022-11-30
GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately t… Ended

2023-504737-41-00 Moderately to Severely Active Crohn's Disease 5 2022-06-10
A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504736-18-00 Moderately to Severely Active Crohn's Disease 10 2018-07-26
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants with Moderate to Severe Ulcerative Colitis Ended

2022-503005-38-00 Ulcerative Colitis 4 2023-12-04
A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and … Ended

2022-502778-18-00 ulcerative colitis 5 2023-11-17
A clinical study of tulisokibart for the treatment of ulcerative colitis (MK-7240-005) Ended

2023-509741-12-00 Ulcerative Colitis 4 2021-09-23